• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ST1
Click for more information
1.75% 5.6¢

SPIRIT TECHNOLOGY SOLUTIONS LTD - Charts / Financials

Market Cap $103.3M  ! watchlist Created with Sketch. Add to my watchlist
Communication Services Telecom Services

ST1 is leading the disruption of IT&T industry. We’ve developed our own advanced fixed... ST1 is leading the disruption of IT&T industry. We’ve developed our own advanced fixed wireless network, which means we can provide Australian small to medium sized-businesses (SMBs) with Sky-Speed Internet, along with Managed IT Services and cloud-based business solutionsMore

refresh Created with Sketch. REFRESH
Last update - 10.09am 02/10/2024 (20 minute delay) ?
Day
Open 5.7¢   Day High 5.7¢   Day Low 5.6¢
Daily Volume 609645
Bids   Sellers
Number Price Volume   Number Price Volume
1 5.6¢ 66093   2 5.8¢ 37674

Directors & Senior Management

Mr. Julian Challingsworth Chief Executive Officer, Managing Director, Executive Director
Mr. Paul Miller Chief Financial Officer
Mr. James Joughin Non-Executive Chairman of the Board
Mr. Shan Shamsher Kanji Non-Independent Non-Executive Director
Mr. Simon Mckay Non-Executive Director
Mr. Dane Meah Non-Executive Director
Ms. Lynn Warneke Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
5.6¢ 		Change
-0.001(1.75%) 		Mkt cap ! $103.3M
Open High Low Value Volume
5.7¢ 5.7¢ 5.6¢ $34.14K 609.6K

Buyers (Bids)

No. Vol. Price($)
1 66093 5.6¢
 

Sellers (Offers)

Price($) Vol. No.
5.8¢ 37674 2
View Market Depth
Last trade - 10.09am 02/10/2024 (20 minute delay) ?
Last
5.6¢ 		  Change
-0.001 ( 1.75 %)
Open High Low Volume
5.6¢ 5.6¢ 5.6¢ 6309
Last updated 10.09am 02/10/2024 ?

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t Maximus Resources (ASX:MXR) has unveiled its latest drilling assay results at Eagles Nest, hitting gold downhole multiple assets.
PainChek close to finding out if FDA approves its flagship app for use in dementia care PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.